SYNTARA LIMITED - Announcements

Market Cap $41.29M Add to my watchlist

Healthcare

Syntara Limited is an Australia-based clinical-stage drug development company. The... Syntara Limited is an Australia-based clinical-stage drug development company. The Company is targeting extracellular matrix dysfunction with its amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The Company’s lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its product candidate, SNT-4728, is an inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

SNT	Exercise of Employee Options		31/05/10	96.29KB	Share
SNT	Sustained Benefit Following 18 Month Bronchitol Treatment	PRICE SENSITIVE	17/05/10	45.53KB	Share
SNT	Appendix 3B - Exercise of Employee Options		30/04/10	96.28KB	Share
SNT	Pharmaxis resubmission for Aridol US marketing application		27/04/10	87.28KB	Share
SNT	Appendix 3B - Exercise of Employee Options		23/04/10	96.32KB	Share
SNT	Change in substantial holding		22/04/10	80.7KB	Share
SNT	Appendix 4C - quarterly March 2010	PRICE SENSITIVE	14/04/10	116.43KB	Share
SNT	March 2010 Quarterly Report to Shareholders		14/04/10	428.91KB	Share
SNT	Pharmaxis Announces Milestone in Phase 3 Trial for CF	PRICE SENSITIVE	14/04/10	25.5KB	Share
SNT	PHARMAXIS QUARTERLY INVESTOR CONFERENCE CALL		12/04/10	21.59KB	Share
SNT	Appendix 3B - Exercise of Employee Options		23/03/10	96.31KB	Share
SNT	Disclosure notice under section 708A(5)(e)		15/03/10	38.46KB	Share
SNT	Appendix 3B - Topigen Milestone Payment		15/03/10	95.04KB	Share
SNT	Pharmaxis Completes Phase II Clinical Study with ASM8	PRICE SENSITIVE	11/03/10	106.53KB	Share
SNT	Change in substantial holding		10/03/10	57.75KB	Share
SNT	Investor Presentation		02/03/10	2.66MB	Share
SNT	Disclosure notice under section 708A(5) of Corporations Act		09/02/10	38.42KB	Share
SNT	Appendix 3B - Topigen Acquisition		09/02/10	95.08KB	Share
SNT	Pharmaxis completes acquisition of Topigen Pharmaceuticals		09/02/10	23.07KB	Share
SNT	Pharmaxis completes clinical trial with PXS25	PRICE SENSITIVE	09/02/10	30.49KB	Share
SNT	Appendix 3B - Exercise of Employee Options		05/02/10	96.33KB	Share
SNT	Half Yearly Report and Accounts	PRICE SENSITIVE	05/02/10	548.45KB	Share
SNT	Updated Investor Presentation		28/01/10	2.02MB	Share
SNT	Appendix 4C - Quarterly Cash Flow	PRICE SENSITIVE	27/01/10	109.9KB	Share
SNT	December 2009 Quarterly Report to Shareholders		27/01/10	253.81KB	Share
SNT	Investor Conference Call		22/01/10	21.65KB	Share
SNT	Pharmaxis to acquire Canadian company TOPIGEN Pharmaceutical	PRICE SENSITIVE	12/01/10	29.99KB	Share
SNT	Pharmaxis receives response letter from the FDA on Aridol	PRICE SENSITIVE	29/12/09	63.73KB	Share
SNT	Pharmaxis lodges TGA application to market Bronchitol for CF	PRICE SENSITIVE	17/12/09	24.45KB	Share
SNT	Exercise of Employee Options		09/12/09	96.32KB	Share
SNT	Change of Director's Interest Notice		08/12/09	13.97KB	Share
SNT	Change in substantial holding		03/12/09	88.64KB	Share
SNT	PHARMAXIS ANNOUNCES SUSTAINED BENEFIT WITH BRONCHITOL	PRICE SENSITIVE	02/12/09	28.24KB	Share
SNT	Change of Director's Interest Notice - Appendix 3Y		26/11/09	14.32KB	Share
SNT	Appendix 3B - Exercise of Employee Options		26/11/09	96.29KB	Share
SNT	FDA Advisory Committee Recommends Approval of Aridol		23/11/09	77.25KB	Share
SNT	Pharmaxis Applies to Market Bronchitol for CF in Europe	PRICE SENSITIVE	29/10/09	23.8KB	Share
SNT	Appendix 3B - Exercise of Employee Options		27/10/09	97.59KB	Share
SNT	Commencement of Bronchiectasis Study and Aligning Strategy	PRICE SENSITIVE	23/10/09	25.37KB	Share
SNT	Appendix 3Y - Mr Richard van den Broek		22/10/09	14.36KB	Share
SNT	Appendix 3Y - Dr Alan Robertson		22/10/09	14.28KB	Share
SNT	Appendix 3B		22/10/09	83.9KB	Share
SNT	Final Director's Interest Notice		22/10/09	10.96KB	Share
SNT	Results of Meeting		22/10/09	84.08KB	Share
SNT	CEO Presentation to AGM 2009		21/10/09	2.23MB	Share
SNT	Chairman's Address to Shareholders 2009 AGM		21/10/09	26.81KB	Share
SNT	Investor Presentation - Quarterly Conference Call		14/10/09	1.19MB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	14/10/09	109.65KB	Share
SNT	Pharmaxis Quarterly Report to Shareholders - Sept 2009		14/10/09	334.94KB	Share
SNT	Quarterly Investor Conference Call		13/10/09	21.67KB	Share
SNT	Second CF Trial Passes Recruitment Target	PRICE SENSITIVE	18/09/09	25.01KB	Share
SNT	Appendix 3B - Exercise of Employee Options		15/09/09	96.39KB	Share
SNT	Pharmaxis 2009 Statutory Annual Report		11/09/09	811.23KB	Share
SNT	Notice of General Meeting/Proxy Form		11/09/09	327.45KB	Share
SNT	Pharmaxis 2009 Annual Review		11/09/09	430.71KB	Share
SNT	PHARMAXIS TO PRESENT AT EUROPEAN RESPIRATORY SOCIETY MEETING		11/09/09	26.18KB	Share
SNT	Proposed Issue of Securities to Non Executive Director		04/09/09	77.23KB	Share
SNT	Appendix 3B - Exercise of Employee Options		14/08/09	96.28KB	Share
SNT	Preliminary Final Report	PRICE SENSITIVE	14/08/09	210.62KB	Share
SNT	Exercise of Employee Options		04/08/09	96.41KB	Share
SNT	Exercise of Employee Options		24/07/09	96.37KB	Share
SNT	Appendix 4C - Quarterly Cash Flow	PRICE SENSITIVE	22/07/09	109.92KB	Share
SNT	Investor Conference Call Presentation		22/07/09	609.32KB	Share
SNT	Quarterly Report to Shareholders June 2009		22/07/09	385.9KB	Share
SNT	Pharmaxis Investor Conference Call		21/07/09	21.73KB	Share
SNT	Pharmaxis to Voluntarily De-List from Nasdaq		13/07/09	21.92KB	Share
SNT	Amended Appendix 3Y		06/07/09	54.18KB	Share
SNT	Appendix 3Y		06/07/09	14.75KB	Share
SNT	Appendix 3B - Exercise of Employee Options		01/07/09	96.35KB	Share
SNT	Appendix 3B - Share Purchase Plan		30/06/09	96.48KB	Share
SNT	Pharmaxis Closes Share Purchase Plan		30/06/09	22.37KB	Share
SNT	Proposed Issue of Employee Options		23/06/09	79.76KB	Share
SNT	Appendix 3B - Annual Issue of Employee Options		23/06/09	97.58KB	Share
SNT	Amended Phase 3 Additional Results		16/06/09	74.46KB	Share
SNT	Phase 3 CF Trial Results Presented at European Conference	PRICE SENSITIVE	16/06/09	34.86KB	Share
SNT	Disclosure Notice Under Section 708A(5)(e)		11/06/09	38.25KB	Share
SNT	Exercise of Employee Options		10/06/09	96.3KB	Share
SNT	Appendix 3B - Placement		04/06/09	96.42KB	Share
SNT	Pharmaxis Announces Placement of $47 Million and SPP	PRICE SENSITIVE	04/06/09	24.23KB	Share
SNT	Trading Halt	PRICE SENSITIVE	02/06/09	63.42KB	Share
SNT	US FDA Accepts Aridol New Drug Application for Review	PRICE SENSITIVE	14/05/09	25.36KB	Share
SNT	Updated Investor Presentation		07/05/09	1.99MB	Share
SNT	Pharmaxis Announces Positive Results of Phase 3 CF Trial	PRICE SENSITIVE	04/05/09	36.75KB	Share
SNT	Trading Halt	PRICE SENSITIVE	04/05/09	58.96KB	Share
SNT	Appendix 3B - Employee Options		01/05/09	98.74KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	08/04/09	56.82KB	Share
SNT	Quarterly Report to Shareholders - March 2009		08/04/09	526.11KB	Share
SNT	Initial Director's Interest Notice		07/04/09	15.27KB	Share
SNT	Director Appointment		07/04/09	24.56KB	Share
SNT	Quarterly Report to Shareholders and InvestorConference Call		06/04/09	24.39KB	Share
SNT	Pharmaxis Announces Milestone in Phase III Trial for CF	PRICE SENSITIVE	01/04/09	29.24KB	Share
SNT	Change in substantial holding		27/03/09	57.86KB	Share
SNT	Pharmaxis Appoints French Distributor for Aridol	PRICE SENSITIVE	11/03/09	27.4KB	Share
SNT	Aridol New Drug Application Submitted to FDA	PRICE SENSITIVE	02/03/09	28.48KB	Share
SNT	Pharmaxis Builds Senior Management Team		17/02/09	24.19KB	Share
SNT	Change in substantial holding		13/02/09	84.46KB	Share
SNT	Appendix 3B Employee Options		09/02/09	103.37KB	Share
SNT	Half Yearly Report - December 2008	PRICE SENSITIVE	06/02/09	185.36KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	28/01/09	56.69KB	Share
SNT	Quarterly Report to Shareholders December 2008		28/01/09	350.68KB	Share

SNTExercise of Employee Options
31/05/10		96.29KB	Share
SNTSustained Benefit Following 18 Month Bronchitol Treatment
17/05/10	PRICE SENSITIVE	45.53KB	Share
SNTAppendix 3B - Exercise of Employee Options
30/04/10		96.28KB	Share
SNTPharmaxis resubmission for Aridol US marketing application
27/04/10		87.28KB	Share
SNTAppendix 3B - Exercise of Employee Options
23/04/10		96.32KB	Share
SNTChange in substantial holding
22/04/10		80.7KB	Share
SNTAppendix 4C - quarterly March 2010
14/04/10	PRICE SENSITIVE	116.43KB	Share
SNTMarch 2010 Quarterly Report to Shareholders
14/04/10		428.91KB	Share
SNTPharmaxis Announces Milestone in Phase 3 Trial for CF
14/04/10	PRICE SENSITIVE	25.5KB	Share
SNTPHARMAXIS QUARTERLY INVESTOR CONFERENCE CALL
12/04/10		21.59KB	Share
SNTAppendix 3B - Exercise of Employee Options
23/03/10		96.31KB	Share
SNTDisclosure notice under section 708A(5)(e)
15/03/10		38.46KB	Share
SNTAppendix 3B - Topigen Milestone Payment
15/03/10		95.04KB	Share
SNTPharmaxis Completes Phase II Clinical Study with ASM8
11/03/10	PRICE SENSITIVE	106.53KB	Share
SNTChange in substantial holding
10/03/10		57.75KB	Share
SNTInvestor Presentation
02/03/10		2.66MB	Share
SNTDisclosure notice under section 708A(5) of Corporations Act
09/02/10		38.42KB	Share
SNTAppendix 3B - Topigen Acquisition
09/02/10		95.08KB	Share
SNTPharmaxis completes acquisition of Topigen Pharmaceuticals
09/02/10		23.07KB	Share
SNTPharmaxis completes clinical trial with PXS25
09/02/10	PRICE SENSITIVE	30.49KB	Share
SNTAppendix 3B - Exercise of Employee Options
05/02/10		96.33KB	Share
SNTHalf Yearly Report and Accounts
05/02/10	PRICE SENSITIVE	548.45KB	Share
SNTUpdated Investor Presentation
28/01/10		2.02MB	Share
SNTAppendix 4C - Quarterly Cash Flow
27/01/10	PRICE SENSITIVE	109.9KB	Share
SNTDecember 2009 Quarterly Report to Shareholders
27/01/10		253.81KB	Share
SNTInvestor Conference Call
22/01/10		21.65KB	Share
SNTPharmaxis to acquire Canadian company TOPIGEN Pharmaceutical
12/01/10	PRICE SENSITIVE	29.99KB	Share
SNTPharmaxis receives response letter from the FDA on Aridol
29/12/09	PRICE SENSITIVE	63.73KB	Share
SNTPharmaxis lodges TGA application to market Bronchitol for CF
17/12/09	PRICE SENSITIVE	24.45KB	Share
SNTExercise of Employee Options
09/12/09		96.32KB	Share
SNTChange of Director's Interest Notice
08/12/09		13.97KB	Share
SNTChange in substantial holding
03/12/09		88.64KB	Share
SNTPHARMAXIS ANNOUNCES SUSTAINED BENEFIT WITH BRONCHITOL
02/12/09	PRICE SENSITIVE	28.24KB	Share
SNTChange of Director's Interest Notice - Appendix 3Y
26/11/09		14.32KB	Share
SNTAppendix 3B - Exercise of Employee Options
26/11/09		96.29KB	Share
SNTFDA Advisory Committee Recommends Approval of Aridol
23/11/09		77.25KB	Share
SNTPharmaxis Applies to Market Bronchitol for CF in Europe
29/10/09	PRICE SENSITIVE	23.8KB	Share
SNTAppendix 3B - Exercise of Employee Options
27/10/09		97.59KB	Share
SNTCommencement of Bronchiectasis Study and Aligning Strategy
23/10/09	PRICE SENSITIVE	25.37KB	Share
SNTAppendix 3Y - Mr Richard van den Broek
22/10/09		14.36KB	Share
SNTAppendix 3Y - Dr Alan Robertson
22/10/09		14.28KB	Share
SNTAppendix 3B
22/10/09		83.9KB	Share
SNTFinal Director's Interest Notice
22/10/09		10.96KB	Share
SNTResults of Meeting
22/10/09		84.08KB	Share
SNTCEO Presentation to AGM 2009
21/10/09		2.23MB	Share
SNTChairman's Address to Shareholders 2009 AGM
21/10/09		26.81KB	Share
SNTInvestor Presentation - Quarterly Conference Call
14/10/09		1.19MB	Share
SNTAppendix 4C - quarterly
14/10/09	PRICE SENSITIVE	109.65KB	Share
SNTPharmaxis Quarterly Report to Shareholders - Sept 2009
14/10/09		334.94KB	Share
SNTQuarterly Investor Conference Call
13/10/09		21.67KB	Share
SNTSecond CF Trial Passes Recruitment Target
18/09/09	PRICE SENSITIVE	25.01KB	Share
SNTAppendix 3B - Exercise of Employee Options
15/09/09		96.39KB	Share
SNTPharmaxis 2009 Statutory Annual Report
11/09/09		811.23KB	Share
SNTNotice of General Meeting/Proxy Form
11/09/09		327.45KB	Share
SNTPharmaxis 2009 Annual Review
11/09/09		430.71KB	Share
SNTPHARMAXIS TO PRESENT AT EUROPEAN RESPIRATORY SOCIETY MEETING
11/09/09		26.18KB	Share
SNTProposed Issue of Securities to Non Executive Director
04/09/09		77.23KB	Share
SNTAppendix 3B - Exercise of Employee Options
14/08/09		96.28KB	Share
SNTPreliminary Final Report
14/08/09	PRICE SENSITIVE	210.62KB	Share
SNTExercise of Employee Options
04/08/09		96.41KB	Share
SNTExercise of Employee Options
24/07/09		96.37KB	Share
SNTAppendix 4C - Quarterly Cash Flow
22/07/09	PRICE SENSITIVE	109.92KB	Share
SNTInvestor Conference Call Presentation
22/07/09		609.32KB	Share
SNTQuarterly Report to Shareholders June 2009
22/07/09		385.9KB	Share
SNTPharmaxis Investor Conference Call
21/07/09		21.73KB	Share
SNTPharmaxis to Voluntarily De-List from Nasdaq
13/07/09		21.92KB	Share
SNTAmended Appendix 3Y
06/07/09		54.18KB	Share
SNTAppendix 3Y
06/07/09		14.75KB	Share
SNTAppendix 3B - Exercise of Employee Options
01/07/09		96.35KB	Share
SNTAppendix 3B - Share Purchase Plan
30/06/09		96.48KB	Share
SNTPharmaxis Closes Share Purchase Plan
30/06/09		22.37KB	Share
SNTProposed Issue of Employee Options
23/06/09		79.76KB	Share
SNTAppendix 3B - Annual Issue of Employee Options
23/06/09		97.58KB	Share
SNTAmended Phase 3 Additional Results
16/06/09		74.46KB	Share
SNTPhase 3 CF Trial Results Presented at European Conference
16/06/09	PRICE SENSITIVE	34.86KB	Share
SNTDisclosure Notice Under Section 708A(5)(e)
11/06/09		38.25KB	Share
SNTExercise of Employee Options
10/06/09		96.3KB	Share
SNTAppendix 3B - Placement
04/06/09		96.42KB	Share
SNTPharmaxis Announces Placement of $47 Million and SPP
04/06/09	PRICE SENSITIVE	24.23KB	Share
SNTTrading Halt
02/06/09	PRICE SENSITIVE	63.42KB	Share
SNTUS FDA Accepts Aridol New Drug Application for Review
14/05/09	PRICE SENSITIVE	25.36KB	Share
SNTUpdated Investor Presentation
07/05/09		1.99MB	Share
SNTPharmaxis Announces Positive Results of Phase 3 CF Trial
04/05/09	PRICE SENSITIVE	36.75KB	Share
SNTTrading Halt
04/05/09	PRICE SENSITIVE	58.96KB	Share
SNTAppendix 3B - Employee Options
01/05/09		98.74KB	Share
SNTAppendix 4C - quarterly
08/04/09	PRICE SENSITIVE	56.82KB	Share
SNTQuarterly Report to Shareholders - March 2009
08/04/09		526.11KB	Share
SNTInitial Director's Interest Notice
07/04/09		15.27KB	Share
SNTDirector Appointment
07/04/09		24.56KB	Share
SNTQuarterly Report to Shareholders and InvestorConference Call
06/04/09		24.39KB	Share
SNTPharmaxis Announces Milestone in Phase III Trial for CF
01/04/09	PRICE SENSITIVE	29.24KB	Share
SNTChange in substantial holding
27/03/09		57.86KB	Share
SNTPharmaxis Appoints French Distributor for Aridol
11/03/09	PRICE SENSITIVE	27.4KB	Share
SNTAridol New Drug Application Submitted to FDA
02/03/09	PRICE SENSITIVE	28.48KB	Share
SNTPharmaxis Builds Senior Management Team
17/02/09		24.19KB	Share
SNTChange in substantial holding
13/02/09		84.46KB	Share
SNTAppendix 3B Employee Options
09/02/09		103.37KB	Share
SNTHalf Yearly Report - December 2008
06/02/09	PRICE SENSITIVE	185.36KB	Share
SNTAppendix 4C - quarterly
28/01/09	PRICE SENSITIVE	56.69KB	Share
SNTQuarterly Report to Shareholders December 2008
28/01/09		350.68KB	Share

REFRESH

First 7 8 9 10 11

(20min delay)
Last 3.1¢		Change -0.001(3.13%)		Mkt cap ! $41.29M

Open	High	Low	Value	Volume
3.2¢	3.2¢	3.1¢	$21.44K	688.3K

Buyers (Bids)

No.	Vol.	Price($)
4	1446000	3.0¢

Sellers (Offers)

Price($)	Vol.	No.
3.2¢	41994	3

View Market Depth

No.	Vol.	Price($)
4	1446000	0.030
6	1620012	0.029
5	1585714	0.028
1	1000000	0.027
3	1255384	0.026

Price($)	Vol.	No.
0.032	41994	3
0.033	586257	3
0.034	1000000	1
0.035	55001	2
0.036	18000	1

Last trade - 14.16pm 16/08/2024 (20 minute delay)


Last 3.1¢		Change -0.001 ( 0.00 %)
Open	High	Low	Volume
3.2¢	3.2¢	3.1¢	570518
Last updated 14.16pm 16/08/2024 ?

SNT (ASX) Chart

SYNTARA LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available